

Pharmacy and Therapeutics (P&T) Committee Meeting March, 21st 2017

Agenda

<u>Topic</u>	<u>Presenter</u>
I. Welcome	Ira Protas
<ul style="list-style-type: none"> • Call to Order 	
II. Introductions	Ira Protas
<ul style="list-style-type: none"> • Ira Protas, RPh – Director of Pharmacy Benefits-Chair • Carl Antolick III, PharmD – Clinical Pharmacist 	
III. Conflict of Interest Statement	Lotta Crabtree, JD
IV. Minutes from December, 28th 2016 Meeting	Jamilah Brunson, PharmD
V. Old Business	Jamilah Brunson, PharmD
<ul style="list-style-type: none"> • SHP Formulary Customization Decision • CVS Implementation • Formulary Development and Management at CVS Caremark® 	
VI. Light Meal	
VII. 2017 Q2 Formulary Updates	Jamilah Brunson, PharmD
<ul style="list-style-type: none"> • Removal of Hyperinflation Products • New to Market Blocked Removals (Formulary Additions) • Products Changing Tiers 	Carl Antolick III, PharmD
VIII. Utilization Management Policy Review	Jamilah Brunson, PharmD
<ul style="list-style-type: none"> • Attention Deficit Hyperactivity Disorder (ADHD) Agents • Insomnia Agents • Narcolepsy Agents • Long Acting Beta Agonists Policy • Short Acting Beta Agonists Policy 	
IX. Other Topics	Jamilah Brunson, PharmD
<ul style="list-style-type: none"> • Formulary Omissions • Formulary Documents 	
X. Next Meeting Date	Ira Protas
<ul style="list-style-type: none"> • May 23rd 2017 • Directions 	